Health
In an early-stage trial, a single dose of a CRISPR treatment lowered cholesterol levels, possibly permanently
A light micrograph cross-section showing cholesterol-containing plaque in a heart artery
NIGEL DOWNER/SCIENCE PHOTO LIBRARY
The prospects for a one-time treatment that reduces the risk of heart disease for the rest of a person’s life just got brighter. In an initial trial, a single dose of a CRISPR gene-editing therapy lowered cholesterol levels without any serious side effects.
The “Heart-2” trial – organised by the biotech company Verve Therapeutics in Boston – involved 14 people who either had an inherited condition leading to very high cholesterol or had developed heart disease at a young age. While this was an early-stage trial…
More from New Scientist
Explore the latest news, articles and features
